Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 6/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.57 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31289571 | 1.00 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1C5AR1F2 | |
| SCHEMBL31289572 | 0.99 | BDKRB2 (0.66) | BDKRB2OPRM1OPRD1C5AR1F2 | |
| SCHEMBL25335885 | 0.99 | BDKRB2 (0.68) | BDKRB2OPRM1OPRD1C5AR1F2 | |
| SCHEMBL30526215 | 0.99 | BDKRB2 (0.68) | BDKRB2OPRM1OPRD1C5AR1F2 | |
| SCHEMBL30549403 | 0.96 | BDKRB2 (0.63) | BDKRB2OPRM1OPRD1C5AR1F2 | |
| SCHEMBL30672572 | 0.96 | BDKRB2 (0.72) | BDKRB2OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL31289567 | 0.95 | BDKRB2 (0.59) | BDKRB2OPRM1OPRD1F2NMUR2 | |
| SCHEMBL29496923 | 0.94 | BDKRB2 (0.62) | BDKRB2OPRM1OPRD1C5AR1F2 | |
| SCHEMBL31289576 | 0.94 | BDKRB2 (0.58) | BDKRB2OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL30526200 | 0.93 | BDKRB2 (0.61) | BDKRB2OPRM1OPRD1C5AR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | SANOFI (FR) | 2026-02-24 | — | — | US | disclosed |
| US-20230399388-A1 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN | SANOFI (FR) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | BDKRB2, KLKB1, BDKRB1 | BDKRB2 1/4885OPRM1 945/4885OPRD1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.